Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 10 Oct 2024
Reviewer:  Hasan Cagri Yildirim
Reviewer's report:
Biliary tract cancers are a very heterogeneous group, and gallbladder cancers and intra- and
extrahepatic cholangiocarcinoma have quite different courses. I would like to thank the authors
for their extensive studies including gallbladder cancers.
My suggestions regarding the article are as follows.
In the method section, it is stated that the study is retrospective, but it contradicts the statement
‘Twelve patients withdrew consent before treatment, and 10 patients were lost to follow-up after
one course of treatment (Fig. 1).’ Was it prospectively followed and written retrospectively?
Figure 2 is not fully understood, were OS and PSF analysis performed as multivariate COX
regression analysis including all patients? Why weren’t univariate analysis performed first and
then the factors that were significant in univariate analysis evaluated with multivariate analysis?
If this patient group specified in Figure 2 is all patients, express it as all patients.
How was it understood from the analysis in Figure 2 that there was no difference in pre-treatment
conditions between the two groups of patients?
‘Measured according to RECIST 1.1, the tumors shrunk by over 30%, reaching a partial reaction
degree.’ You can specify the sentence as partial response was achieved in 30% of patients
Correct the CA199 expression in Table 3 to CA19-9
There are currently two different IO-chemotherapy combinations recommended in international
guidelines for the treatment of biliary tract cancer, and it is recommended that authors include
these articles in the discussion section.
In the article evaluating the medical treatment of advanced gallbladder cancer, it is not
understood why the medical oncology specialists who actually apply these treatments are not
the authors (according to the affiliations on the title page)
Best regards
Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 10 Oct 2024
Reviewer:  Hasan Cagri Yildirim
Reviewer's report:
Biliary tract cancers are a very heterogeneous group, and gallbladder cancers and intra- and
extrahepatic cholangiocarcinoma have quite different courses. I would like to thank the authors
for their extensive studies including gallbladder cancers.
My suggestions regarding the article are as follows.
In the method section, it is stated that the study is retrospective, but it contradicts the statement
‘Twelve patients withdrew consent before treatment, and 10 patients were lost to follow-up after
one course of treatment (Fig. 1).’ Was it prospectively followed and written retrospectively?
Figure 2 is not fully understood, were OS and PSF analysis performed as multivariate COX
regression analysis including all patients? Why weren’t univariate analysis performed first and
then the factors that were significant in univariate analysis evaluated with multivariate analysis?
If this patient group specified in Figure 2 is all patients, express it as all patients.
How was it understood from the analysis in Figure 2 that there was no difference in pre-treatment
conditions between the two groups of patients?
‘Measured according to RECIST 1.1, the tumors shrunk by over 30%, reaching a partial reaction
degree.’ You can specify the sentence as partial response was achieved in 30% of patients
Correct the CA199 expression in Table 3 to CA19-9
There are currently two different IO-chemotherapy combinations recommended in international
guidelines for the treatment of biliary tract cancer, and it is recommended that authors include
these articles in the discussion section.
In the article evaluating the medical treatment of advanced gallbladder cancer, it is not
understood why the medical oncology specialists who actually apply these treatments are not
the authors (according to the affiliations on the title page)
Best regards
Please review this paper.
user
Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 10 Oct 2024
Reviewer:  Hasan Cagri Yildirim
Reviewer's report:
Biliary tract cancers are a very heterogeneous group, and gallbladder cancers and intra- and
extrahepatic cholangiocarcinoma have quite different courses. I would like to thank the authors
for their extensive studies including gallbladder cancers.
My suggestions regarding the article are as follows.
In the method section, it is stated that the study is retrospective, but it contradicts the statement
‘Twelve patients withdrew consent before treatment, and 10 patients were lost to follow-up after
one course of treatment (Fig. 1).’ Was it prospectively followed and written retrospectively?
Figure 2 is not fully understood, were OS and PSF analysis performed as multivariate COX
regression analysis including all patients? Why weren’t univariate analysis performed first and
then the factors that were significant in univariate analysis evaluated with multivariate analysis?
If this patient group specified in Figure 2 is all patients, express it as all patients.
How was it understood from the analysis in Figure 2 that there was no difference in pre-treatment
conditions between the two groups of patients?
‘Measured according to RECIST 1.1, the tumors shrunk by over 30%, reaching a partial reaction
degree.’ You can specify the sentence as partial response was achieved in 30% of patients
Correct the CA199 expression in Table 3 to CA19-9
There are currently two different IO-chemotherapy combinations recommended in international
guidelines for the treatment of biliary tract cancer, and it is recommended that authors include
these articles in the discussion section.
In the article evaluating the medical treatment of advanced gallbladder cancer, it is not
understood why the medical oncology specialists who actually apply these treatments are not
the authors (according to the affiliations on the title page)
Best regards
assistant